A systematic review of the cardiotoxicity of methadone

EXCLI Journal

Volumn 14, Issue , 2015, Pages 577-600

  Alinejad, Samira ^a   Kazemi, Toba ^a   Zamani, Nasim ^b   Hoffman, Robert S ^c   Mehrpour, Omid ^d  

^a BIRJAND UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BIRJAND UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ECG; Heart; Methadone; QT interval; Torsade de pointes; Toxicity

Indexed keywords

BUPRENORPHINE; CHARCOAL; MAGNESIUM; METHADONE; POTASSIUM;

BRUGADA SYNDROME; CARDIOTOXICITY; CHILDHOOD DISEASE; CORONARY ARTERY DISEASE; CORONARY HEMODYNAMICS; DEFIBRILLATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; ELECTROCARDIOGRAM; HEART MUSCLE POTENTIAL; HEART VENTRICLE BIGEMINY; HUMAN; HYPOKALEMIA; NONHUMAN; OPIATE ADDICTION; PAIN; PREGNANCY; QT DISPERSION; QT INTERVAL; QT PROLONGATION; REVIEW; SYSTEMATIC REVIEW; TAKOTSUBO CARDIOMYOPATHY; TORSADE DES POINTES; U WAVE;

SCOPUS;

EID: 84930193959     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: 10.17179/excli2014-553     Document Type: Review

References (169)

1. Abramson DW, Quinn DK, Stern TA. Methadone-associated QTc prolongation: a case report and review of the literature. Prim Care Companion J Clin Psychiatry. 2008;10:470-6.
2. Afshari R, Maxwell S, Bateman D. Hemodynamic effects of methadone and dihydrocodeine in overdose. Clin Toxicol. 2007;45:763-72.
3. Almehmi A, Malas AM, Yousufuddin M, Rosen-crance JG. Methadone-induced torsade de pointes in a patient with normal baseline QT interval. W V Med J. 2003;100:147-8.
4. Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104:993-9.
5. Anchersen K, Hansteen V, Gossop M, Clausen T, Waal H. Opioid maintenance patients with QTc prolongation: Congenital long QT syndrome mutation may be a contributing risk factor. Drug Alcohol Depend. 2010;112:216-9.
6. Anderson DM, Alvarado SJ. Hemodynamic effects of intravenous methadone. Anesthesiology. 2003;99: A190.
7. Anderson IB, Kearney TE. Use of methadone. Western J Med. 2000;172:43-6.
8. Anguera I, Gil M, Sla M, Chapinal O, Cervantes M, Guè JR, et al. Syncope due to torsade de pointes in an HIV‐infected patient receiving methadone treatment. Syncope Cases. 2008;165-7.
9. Ansermot N, Albayrak O, Schläpfer J, Crettol S, Croquette-Krokar M, Bourquin M, et al. Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med. 2010;170:529-36.
10. Athanasos P, Farquharson AL, Compton P, Psaltis P, Hay J. Electrocardiogram characteristics of metha-done and buprenorphine maintained subjects. J Addict Dis. 2008;27:31-5.
11. Atkinson D, Dunne A, Parker M. Torsades de pointes and self‐terminating ventricular fibrillation in a prescription methadone user. Anaesthesia. 2007;62:952-5.
12. Ayatollahi V, Behdad S, Oliwiaie H, Hajiesmaili MR, Dehghan M, Mehrpour O. Characteristic features of patients hospitalized with Narcotic poisoning in Yazd, Iran. Iran J Toxicol. 2011;4:362-6.
13. Backmund M, Meyer K, Zwehl W, Nagengast O, Eichenlaub D. Myocardial infarction associated with methadone and/or dihydrocodeine. Eur Addict Res. 2001;7:37-9.
14. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis. 2001;43:1-45.
15. Boyer EW, McCance‐Katz EF, Marcus S. Methadone and buprenorphine toxicity in children. Am J Addict. 2010;19:89-95.
16. Burns L, Conroy E, Mattick RP. Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev. 2010;29:551-6.
17. Butler B, Rubin G, Lawrance A, Batey R, Bell J. Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction. Drug Alcohol Rev. 2011;30:173-80.
18. Calver L, Dunlop AJ, Isbister GK. Individual patient assessment of methadone-induced QT prolongation with digital holter recording. J Addict Med. 2012;6: 92-3.
19. Caplehorn JR, Drummer OH. Fatal methadone toxici-ty: signs and circumstances, and the role of benzodia-zepines. Aust N Z J Public Health. 2002;26:358-62.
20. Chana S, Anand K. Can we use methadone for analgesia in neonates? Arch Dis Child-Fetal. 2001; 85:F79-F81.
21. Chang KC, Huang CL, Liang HY, Chang SS, Wang YC, Liang WM, et al. Gender‐specific differences in susceptibility to low‐dose methadone‐associated qtc prolongation in patients with heroin dependence. J Cardiovasc Electr. 2012;23:527-33.
22. Chiang C. Drug-induced long QT syndrome. J Med Biol Eng. 2006;26:107.
23. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med. 2008;121:66-71.
24. Chyka P, Seger D, Krenzelok E, Vale J. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper: single-dose activated charcoal. Clin Toxicol. (Phila) 2005;43:61-87.
25. Cleary BJ, Eogan M, O'Connell MP, Fahey T, Gallagher PJ, Clarke T, et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction. 2012;107:1482-92.
26. Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. Hum Psychopharmacol Clin. 2004;19:565-76.
27. Couper FJ, Chopra K, Pierre-Louis MLY. Fatal methadone intoxication in an infant. Forensic Sci Int. 2005;153:71-3.
28. Cruciani RA. Methadone: to ECG or not to ECG… That is still the question. J Pain Symptom Manag. 2008;36:545-52.
29. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manag. 2005;29:385-91.
30. Davies D, DeVlaming D, Haines C. Methadone analgesia for children with advanced cancer. Pediatr Blood Cancer. 2008;51:393-7.
31. Day C, Nassirimanesh B, Shakeshaft A, Dolan K. Patterns of drug use among a sample of drug users and injecting drug users attending a general practice in Iran. Harm Reduct J. 2006;3:2.
32. De Jong I, De Ruiter G. Buprenorphine as a safe alternative to methadone in a patient with acquired long QT syndrome: a case report. Neth Heart J. 2013;21: 249-52.
33. Deamer RL, Wilson DR, Clark DS, Prichard JG. Tor-sades de pointes associated with high dose levometha-dyl acetate (Orlaam®). J Addict Dis. 2001;20:7-15.
34. Drew BJ, Ackermann MD, Funk M, Giebler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings. Circulation. 2010;121: 1047-60.
35. Eap CB, Crettol S, Rougier JS, Schläpfer J, Sintra Grilo L, Déglon JJ, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81:719-28.
36. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Int Med. 2006;166:1280-7.
37. Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharma-cotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf. 2007;6:289-303.
38. Esfahani MA, Vosughi AA, Fatehi MH, Shahsanaee A, Teimuri A. Evaluation of QTc interval in Iranian causalities (Janbazan) of Iran-Iraq war receiving maintenance methadone treatment. J Res Med Sci 2012;17:264-8.
39. Esses JL, Rosman J, Do LT, Schweitzer P, Hanon S. Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes. J Interv Card Electr. 2008;23:117-9.
40. Fahey T, Law F, Cottee H, Astley P. Sudden death in an adult taking methadone: lessons for general practice. Br J Gen Pract. 2003;53:471-2.
41. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93:1051-5.
42. Fareed A, Vayalapalli S, Byrd-Sellers J, Casarella J, Drexler K, Amar R, et al. Onsite QTc interval screening for patients in methadone maintenance treatment. J Addic Dis. 2010;29:15-22.
43. Ferrari A, Coccia CPR, Bertolini A, Sternieri E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50:551-9.
44. Fonseca F, Marti-Almor J, Pastor A, Cladellas M, Farré M, de la Torre R, et al. Prevalence of long QTc interval in methadone maintenance patients. Drug Alcohol Depen. 2009;99:327-32.
45. Fredheim OMS, Borchgrevink PC, Hegrenæs L, Kaasa S, Dale O, Klepstad P. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: A prospective 9-month follow-up study. J Pain Symptom Manag. 2006;32:180-5.
46. Fredheim O, Moksnes K, Borchgrevink P, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesth Scand. 2008;52:879-89.
47. Gallagher R. Methadone: an effective, safe drug of first choice for pain management in frail older adults. Pain Med. 2009;10:319-26.
48. Gallagher DP, Kieran J, Sheehan G, Lambert J, Mahon N, Mallon PW. Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports. Clin Infect Dis. 2008;47:e36-8.
49. Garofalo NA, Teixeira Neto FJ, Pereira CD, Pignaton W, Vicente F, Alvaides RK. Cardiorespiratory and neuroendocrine changes induced by methadone in conscious and in isoflurane anaesthetised dogs. Vet J. 2012;194:398-404.
50. Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, et al. Qt prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol. 2003;92:995-7.
51. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is" normal". J Cardiovasc Electr. 2006;17:333-6.
52. Guay DR. Cardiotoxicity of oral methadone as an analgesic-recommendations for safe use. Clinical Medicine Insights: Therapeutics. 2009;1:1073-101.
53. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153:891-9.
54. Hasnain M, Vieweg WVR, Breden Crouse EL, Hancox JC. Methadone and torsade de pointes: How can we better understand the association?. Am J Med. 2013;126:757-8.
55. Hassanian-Moghaddam H, Amiri H, Zamani N, Rahimi M, Shadnia S, Taherkhani M. QT dispersion and prognostication of the outcome in acute cardiotoxicities: a comparison with SAPS II and APACHE II scoring systems. Cardiovasc Toxicol. 2014;14:129-33.
56. Hnatkova K, Gang Y, Batchvarov VN, Malik M. Precision of QT interval measurement by advanced elec-trocardiographic equipment Pacing. Clin Electrophy-siol. 2006;29:1277-84.
57. Huh B, Park C-H. Retrospective analysis of low-dose methadone and QTc prolongation in chronic pain patients. Korean J Anesthesiol. 2010;58:338-43.
58. Hussain T, Ewer AK. Maternal methadone may cause arrhythmias in neonates. Acta Paediatr. 2007;96:768-9.
59. IngvastLarsson C, Svartberg K, HydbringSandberg E, Bondesson U, Olsson K. Clinical pharmacology of buprenorphine in healthy, lactating goats. J Vet Pharmacol Ther. 2007;30:249-56.
60. IngvastLarsson C, Holgersson A, Bondesson U, Lagerstedt AS, Olsson K. Clinical pharmacology of methadone in dogs. Vet Anaesth Analg. 2010;37:48-56.
61. Isbister GK, Calver L, Van Gorp F, Stokes B, Page CB. Inter-rater reliability of manual QT measurement and prediction of abnormal QT, HR pairs. Clin Toxicol. 2009;47:884-8.
62. Izadi-Mood N, Gheshlaghi F, Salehi Mehrdad AH. Comparative evaluation of different methadone dosage on QT interval. J Iran Soc Anaesth Intens Care. 2008;62:7-13.
63. Jafari S, Rahimi-Movaghar A, Craib KJ, Baharlou S, Mathias R. A follow-up study of drug users in Southern Iran. Addict Res Theory. 2010;18:59-70.
64. Jansson LM, DiPietro J, Elko A. Fetal response to maternal methadone administration. Am J Obstet Gynecol. 2005;193:611-7.
65. John J, Amley X, Bombino G, Gitelis C, Topi B, Hollander G, et al. Torsade de pointes due to metha-done use in a patient with HIV and hepatitis C coin-fection. Cardiol Res Prac. 2010;2010:524764.
66. Junttila MJ, Gonzalez M, Lizotte E, Benito B, Ver-nooy K, Sarkozy A, et al., Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. Circulation. 2008;117:1890-3.
67. Justo D, GalOz A, Paran Y, Goldin Y, Zeltser D. Methadone‐associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid‐dependent patients. Addiction. 2006;101:1333-8.
68. Karir V Bradycardia associated with intravenous methadone administered for sedation in a patient with acute respiratory distress syndrome. Pharmaco-therapy. 2002;22:1196-9.
69. Karrari P, Mehrpour O, Balali-Mood M. Iranian crystal: a misunderstanding of the crystal-meth. J Res Med Sci. 2012;17:203-4.
70. Karrari P, Mehrpour O, Afshari R, Keyler D. Pattern of illicit drug use in patients referred to addiction treatment centres in Birjand, Eastern Iran. J Pak Med Assoc. 2013;63:711-6.
71. Kastelic A, Dubajic G, Strbad E. Slow‐release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction. 2008;103:1837-46.
72. Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K+ currents. J Pharmacol Exp Ther. 2002;303:688-94.
73. Kazemi T. A memorandum of "World Heart Day 2012": Myocardial infarction mortality in women in Birjand, 2008-2009. J Tehran Heart Cent. 2012;7:191.
74. Kazemi T, Sharifzadeh GR, Zarban A, Fesharakinia A, Rezvani MR, Moezy SA. Risk factors for premature myocardial infarction: a matched case-control study. J Res Health Sci. 2011;11:77-82.
75. Khosrojerdi H, Afshari R, Mehrpour O. Should activated charcoal be given after tramadol overdose. DARU. 2013;21:46.
76. Kobek M, Jabłohski C, Kulikowska J, Pieśniak D, Chowaniec C, Gąszczyk-Ożarowski Z. A rare case of lethal methadone intoxication of a 3-week-old infant. Forensic Sci Int Supp Ser. 2009;1:88-90.
77. Kornick CA, Kilborn MJ, Santiago-Palma J, Schul-man G, Thaler HT, Keefe DL, et al., QTc interval prolongation associated with intravenous methadone. Pain. 2003;105:499-506.
78. Koushesh H, Afshari R. A new illicit opioid dependence outbreak, evidence for a combination of opioids and steroids. Drug Chem Toxicol. 2009;32:114-9.
79. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone Ann Intern Med. 2002;137:501-4.
80. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with Torsade de Pointes. Pharmacotherapy. 2003;23:802-5.
81. Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-inter-val dispersion. Pharmacotherapy. 2005a;25:1523-9.
82. Krantz MJ, Rowan SB, Mehler PS. Cocaine-related torsade de pointes in a methadone maintenance patient. J Addict Dis. 2005b;24:53-60.
83. Krook A, Waal H, Hansteen V. [Routine ECG in me-thadone-assisted rehabilitation is wrong prioritization]. Tidsskr Norske laege. 2004;124:2940-1.
84. Kumar P. Use of oral methadone as an analgesic: review of the cardiotoxic side effects. Clinical Medicine Insights: Therapeutics. 2010:2;299-305.
85. Kuryshev YA, Bruening-Wright A, Brown AM, Kirsch GE. Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodyna-mic interactions in cardiac ion channels. J Cardiovasc Pharmacol. 2010;56:420-30.
86. Lamont P, Hunt SC. A twist on torsade: a prolonged QT interval on methadone. J Gen Int Med. 2006;21: C9-C12.
87. Langendorf R, Pick A, Winternitz M. Mechanisms of intermittent ventricular bigeminy i. appearance of ectopic beats dependent upon length of the ventricular cycle, the" rule of Bigeminy". Circulation. 1955;11: 422-30.
88. Laqueille X, Richa S, Kerbage H, Scart-Gres C, Berleur M. [Review of cases of prolonged QTC and wave burst arrhythmia in patients treated with methadone]. L'Encephale. 2012;38:58-63.
89. Leeman LM, Brown SA, Albright B, Skipper B, Hsi A, Rayburn WF. Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates. J Matern Fetal Neonatal Med. 2011;24:955-9.
90. Lemesle F, Lemesle F, Nicola W, Pierre Jonville-Béra A. First case of stress cardiomyopathy as a result of methadone withdrawal secondary to drug-drug interaction. Am J Emerg Med. 2010;28:387.e5-6.
91. Liao D-L, Chen P-C, Chen C-H, Hsieh C-J, Huang Y-F, Shih W-Y, et al. Higher methadone doses are associated with lower mortality in patients of opioid dependence in Taiwan. J Psychiatr Res. 2013;47:1530-4.
92. Lin C, Somberg T, Molnar J, Somberg J. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology. 2008;113:59-65.
93. Lüthi B, Huttner A, Speck R, Mueller N. Methadone-induced Torsade de pointes after stopping lopinavir– ritonavir. Eur J Clin Microbiol. 2007;26:367-9.
94. Maiante AA, Teixeira Neto FJ, Beier SL, Corrente JE, Pedroso CE. Comparison of the cardio‐respiratory effects of methadone and morphine in conscious dogs. J Vet Pharmacol Ther. 2009;32:317-28.
95. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation. Drug Safety. 2001;24:323-51.
96. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res. 2004;11:44-9.
97. Marmor M, Penn A, Widmer K, Levin RI, Maslansky R. Coronary artery disease and opioid use. Am J Cardiol. 2004;93:1295-7.
98. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolariza-tion and conduction in opioid users. Am J Cardiol. 2005;95:915-8.
99. Mayet S, Gossop M, Lintzeris N, Markides V, Strang J. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongatio?. Drug Alcohol Rev. 2011;30:388-96.
100. Mehrpour O. Methamphetamine abuse a new concern in Iran. DARU. 2012;20:73.
101. Mehrpour O. Addiction and seizure ability of tramadol in high-risk patients. Indian J Anaesth. 2013; 57:86-7.
102. Mehrpour O, Sezavar SV. Diagnostic imaging in body packers. Mayo Clin Proc. 2012;7:e53-4.
103. Mehrpour O, Karrari P, Sheikhazadi A. Survey of factors related to criminal behavior in a sample of Iranian substance abusers. J Forensic Leg Med. 2013;20: 1078-81.
104. Miller MA, Bhasin K, Reddy VY, d'Avila A. Left cardiac sympathetic denervation for the treatment of methadone-induced long QT syndrome. Heart Rhythm. 2011;8:1955-7.
105. Movaghar AR, Goodarzi RR, Izadian E, Mohammadi MR, Hosseini M, Vazirian M. The impact of Bam earthquake on substance users in the first 2 weeks: A rapid assessment. J Urban Health. 2005;82:370-7.
106. Nair MK, Patel K, Starer PJ. Ciprofloxacin‐induced torsades de pointes in a methadone‐dependent patient. Addiction. 2008;103:2062-4.
107. Navaneethakrishnan R, Tutty S, Sinha C, Lindow S. The effect of maternal methadone use on the fetal heart pattern: a computerised CTG analysis. BJOG 2006;113:948-50.
108. Nekhayeva IA, Nanovskaya TN, Deshmukh SV, Zha-rikova OL, Hankins GD, Ahmed MS. Bidirectional transfer of methadone across human placenta. Bio-chem Pharmacol. 2005;69:187-97.
109. Noorzurani MHR, Vicknasingam B, Narayanan S. Itraconazole‐induced Torsade de Pointes in a patient receiving methadone substitution therapy. Drug Alcohol Rev. 2009;28:688-90.
110. Palmiere C, Brunel C, Sporkert F, Augsburger M. An unusual case of accidental poisoning: fatal methadone inhalation. J Forensic Sci. 2011;56:1072-5.
111. Pani PP, Trogu E, Maremmani I, Amato L, Minozzi S, Vecchi S, et al. ECG screening for preventing long QTcrelated cardiac morbidity/mortality in methadone treated opioid addicts. Cochrane Database of Systematic Reviews. 2011;(1):1-16.
112. Parikh R, Hussain T, Holder G, Bhoyar A, Ewer A. Maternal methadone therapy increases QTc interval in newborn infants. Arch Dis Child-Fetal. 2011;96: F141-3.
113. Pasquier M, Pantet O, Hugli O, Pruvot E, Buclin T, Waeber G, et al. Prevalence and determinants of QT interval prolongation in medical inpatients. Int Med J. 2012;42:933-40.
114. Patane S, Marte F, Di Bella G, Chiribiri A. Acute myocardial infarction after consumption of aspirin in a chronic methadone user patient. Int J Cardiol. 2007;120:e32-3.
115. Patel AM, Singh JP, Ruskin JN. Role of implantable cardioverter-defibrillators in patients with methadone-induced long QT syndrome. Am J Cardiol. 2008;101: 209-11.
116. Paulozzi LJ, Logan JE, Hall AJ, McKinstry E, Kaplan JA, Crosby AE. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction. 2009;104:1541-8.
117. Pearson EC, Woosley RL. QT prolongation and tor-sades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoep-idemiol Drug Saf. 2005;14:747-53.
118. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected‐QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients - a cross‐sectional study. Addiction. 2007;102:289-300.
119. PerrinTerrin A, Pathak A, LapeyreMestre M. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone‐treated patients in France. Fund Clin Pharmacol. 2011;25: 503-10.
120. Philipp BL, Merewood A, O’Brien S. Methadone and breastfeeding: new horizons. Pediatrics. 2003;111: 1429-30.
121. Pimentel L, Mayo D. Chronic methadone therapy complicated by torsades de pointes: a case report. J Emerg Med. 2008;34:287-90.
122. Price L, Manuel J, Kurz D, Delate T. Methadone and cardiac adverse outcomes: a retrospective study of patients in a managed care organization (S750). J Pain Symptom Manag. 2013;45:448.
123. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratification in the long-QT syndrome. New Engl J Med 2003;348:1866-74.
124. Prosser JM, Mills A, Rhim ES, Perrone J. Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. Int J Emerg Medicine. 2008;1:217-20.
125. Ramirez-Cacho WA, Flores S, Schrader RM, McKay J, Rayburn WR. Effect of chronic maternal metha-done therapy on intrapartum fetal heart rate patterns. J Soc Gynecol Invest. 2006;13:108-11.
126. Raschi E, Ceccarini L, De Ponti F, Recanatini M. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. Expert Opin Drug Met. 2009;5:1005-21.
127. Reinhold JA, Sanoski CA, Russo AM, Cooper JM, Spinler SA. Torsades de pointes associated with methadone and voriconazole. BMJ Case Rep. 2009; 2009:bcr07.2009.2119.
128. Roden D. Cellular basis of drug‐induced torsades de pointes. Brit J Pharmacol. 2008;154:1502-7.
129. Routhier DD, Katz KD, Brooks DE. QTc prolongation and torsades de pointes associated with methadone therapy. J Emerg Med. 2007;32:275-8.
130. Roy AK, McCarthy C, Kiernan G, McGorrian C, Keenan E, Mahon NG, et al. Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. Addiction. 2012;107:1132-9.
131. Safaei N. Outcomes of coronary artery bypass grafting in patients with a history of opiate use. Pak J Biol Sci. 2008;11:2594-8.
132. Saiful FB, Lafferty J, Jun CH, Teli S, Duvvuri S, Khattri S, et al. Takotsubo cardiomyopathy due to iatrogenic methadone withdrawal. Rev Cardiovasc Med. 2010;12:164-7.
133. Sánchez Hernández AM, Atienza Fernández F, Arenal Maíz Á, González Torrecilla E, Puchol Calderón A, Garrote JA. Torsades de pointes during methadone treatment. Rev Esp Cardiol (Engl Ed). 2005;58:1230-2.
134. Sanguinetti MC, Mitcheson JS. Predicting drug– hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci. 2005;26:119-24.
135. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440: 463-9.
136. Schmid M, Kuessel L, Klein K, Metz V, Fischer G, Krampl‐Bettelheim E. First‐trimester fetal heart rate in mothers with opioid addiction. Addiction. 2010; 105:1265-8.
137. Schmidt SK. Getting to the heart of the matter with methadone maintenance-QTc effects. J Addict Nurs. 2005;16:207.
138. Schmittner J, Schroeder JR, Epstein DH, Krantz MJ, Eid NC, Preston KL. Electrocardiographic effects of lofexidine and methadone coadministration: secondary findings from a safety study. Pharmacotherapy. 2009;29:495-502.
139. Scholler J, Nivoix Y, Herbrecht R, Kemmel V, Levê-que D. Ventricular bigeminy associated with vori-conazole, methadone and esomeprazole. Int J Clin Pharm. 2011;33:905-8.
140. Sekine R, Obbens EA, Coyle N, Inturrisi CE. The successful use of parenteral methadone in a patient with a prolonged QTc interval. J Pain Symptom Manag. 2007;34:566-9.
141. Shields LB, Hunsaker III JC, Corey TS, Ward MK, Stewart D. Methadone toxicity fatalities: a review of medical examiner cases in a large metropolitan area. J Forensic Sci. 2007;52:1389-95.
142. Shir Y, Rosen G, Zeldin A, Davidson EM. Methadone is safe for treating hospitalized patients with severe pain. Can J Anesth. 2001;48:1109-13.
143. Siddappa R, Fletcher JE, Heard A, Kielma D, Cimino M, Heard C. Methadone dosage for prevention of opi-oid withdrawal in children. Pediatr Anesth. 2003;13: 805-10.
144. Smith GA, Tsui H-W, Newell EW, Jiang X, Zhu X-P, Tsui FW, et al. Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem. 2002;277:18528-34.
145. Somberg JC, Molnar J. Usefulness of QT dispersion as an electrocardiographically derived index. Am J Cardiol. 2002;89:291-4.
146. Spevak C, Hamsher C, Brown CQ, Wedam EF, Haigney MC. The clinical significance of QT interval prolongation in anesthesia and pain management: what you should and should not worry about. Pain Med. 2012;13:1072-80.
147. Srivatsa U, Hoppe B, Lu J, Feld GK. Sequential appearance of both Brugada and long QT patterns on EKG in a single patient receiving methadone. Heart Rhythm. 2005;2:S50.
148. Stallvik M, Nordstrand B, Kristensen Ø, Bathen J, Skogvoll E, Spigset O. Corrected QT interval during treatment with methadone and buprenorphine -Relation to doses and serum concentrations. Drug Alcohol Depend. 2013;129:88-93.
149. Sticherling C, Schaer BA, Ammann P, Maeder M, Osswald S. Methadone-induced torsade de pointes tachycardias. Swiss Med Wkly. 2005;135:282-5.
150. Stimmel B. QT or not QT, that is the question: routine electrocardiograms for individuals in methadone maintenance treatment. J Addict Dis. 2011;30:307-8.
151. Strain E. Low versus high doses of methadone. Eur Neuropsychopharm. 2002;12:118-9.
152. Taghaddosinejad F, Mehrpour O, Afshari R, Seghato-leslami A, Abdollahi M, Dart RC. Factors related to seizure in tramadol poisoning and its blood concentra-tion. J Med Toxicol.2011;7:183-8.
153. Teichtahl H, Wang D, Cunnington D, Kronborg I, Goodman C, Prodromidis A, et al. Cardiorespiratory function in stable methadone maintenance treatment (MMT) patients. Addict Biol. 2004;9:247-53.
154. Thanavaro KL, Thanavaro JL. Methadone-induced torsades de pointes: A twist of fate. Heart Lung. 2011; 40:448-53.
155. Tünsmeyer J, Vaske B, Bösing B, Kästner SB. Cardiovascular effects of a proprietary l‐methadone/ fenpipramide combination (Polamivet) alone and in addition to acepromazine in healthy Beagle dogs. Vet Anaesth Analg. 2012;39:451-63.
156. Vieweg WV, Hasnain M, Howland RH, Clausen T, Koneru JN, Kogut C, et al., Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem. Ther Adv Psychopharmacol. 2013;3:219-32.
157. Villain E, Levy M, Kachaner J, Garson A. Prolonged QT interval in neonates: benign, transient, or prolonged risk of sudden death. Am Heart J. 1992;124: 194-7.
158. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardio-vasc Dis. 2003;45:415-27.
159. Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain. 2003;103:321-4.
160. Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat. 2013;44:241-7.
161. Wallner C, Stöllberger C, Hlavin A, Finsterer J, Hager I, Hermann P. Electrocardiographic abnormalities in opiate addicts. Addiction. 2008;103:1987-93.
162. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levo-methadyl, and buprenorphine in a randomized trial. Arch Int Med. 2007;167:2469-75.
163. Wheeler AD, Tobias JD. Bradycardia during metha-done therapy in an infant. Pediatric Crit Care Med. 2006;7:83-5.
164. Wilcock A, Beattie JM. Prolonged QT interval and methadone: implications for palliative care. Curr Opin Support Palliat Care. 2009;3:252-7.
165. Winton JC, Twilla JD. Sudden cardiac arrest in a patient on chronic methadone after the addition of azithromycin. Am J Med Sci. 2013;345:160-2.
166. Wood AJ, Berde CB, Sethna NF. Analgesics for the treatment of pain in children. New Engl J Med. 2002;347:1094-103.
167. Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990‐1995. Addiction. 2000;95:77-84.
168. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death:a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). J Am Coll Cardiol. 2006;48:e247-e346.
169. Zünkler BJ, Wos-Maganga M. Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels. Cardiovasc Toxicol. 2010; 10:161-5.